- Diabetes specialist GlucoTrack (NASDAQ:GCTK) achieved another milestone in its development of an implantable continuous glucose monitor (CGM)
- The objectives of the preclinical animal study were to assess the implant procedure techniques and tools as well as to determine the acute and chronic biological effect of the implant and the implant procedure
- The results from the preclinical study have established that the sensor implant procedure takes approximately 15-20 minutes to perform and does not require sophisticated implant techniques or tools
- GlucoTrack Inc. opened trading at $0.31 per share
Diabetes specialist GlucoTrack (NASDAQ:GCTK) achieved another milestone in its development of an implantable continuous glucose monitor (CGM).
The medical device and digital health platform company had announced the completion and positive results of a laboratory-based feasibility study demonstrating that the CGM sensor design is capable of measuring glucose for at least two years post-implant. Further preclinical testing, in animals, advances the development of the implantable CGM by demonstrating that the sensor design functions as expected after an implant procedure and for the next 30 days.
The objectives of the preclinical animal study were to assess the implant procedure techniques and tools as well as to determine the acute and chronic biological effect of the implant and the implant procedure. At this stage of development, the study was not intended to assess sensor measurement accuracy.
The results from the preclinical study have established that the sensor implant procedure takes approximately 15-20 minutes to perform, does not require sophisticated implant techniques or tools and was able to be completed with no adverse short-term (up to three days) or long-term (up to 30 days) effect on the animals.
“This preclinical study is a key step in furthering the development of our long-term implantable CGM enabling us to initiate preparations for a long-term preclinical study to assess sensor performance and accuracy,” Paul Goode, PhD, CEO of Glucotrack said in a news release. “We are pleased to be one step closer to bringing this technology to the millions of people living with diabetes.”
GlucoTrack Inc. is focused on the design, development, and commercialization of novel technologies for people with diabetes and prediabetes. The company’s initial product, GlucoTrack, is a proprietary non-invasive glucose monitoring device.
GlucoTrack Inc. opened trading at $0.31 per share.
Join the discussion: Find out what everybody’s saying about this stock on the GlucoTrack Bullboard.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.